Cyclooxygenase and lipoxygenase inhibitors in cancer therapy.

[1]  Collins,et al.  Similarity of metabolism for CAI (NSC 609974) in human liver tissue in vitro and in humans in vivo , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  V. Steele,et al.  Chemoprevention of Colon Carcinogenesis by Sulindac , a Nonsteroidal Anti-inflammatory Agent 1 , 2022 .

[3]  D. Rose,et al.  Effects of linoleic acid on the growth and metastasis of two human breast cancer cell lines in nude mice and the invasive capacity of these cell lines in vitro. , 1994, Cancer research.

[4]  R. Hansen,et al.  Preclinical and Clinical Activity of Zileuton and A‐78773 , 1993, Annals of the New York Academy of Sciences.

[5]  G. Kelloff,et al.  Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. , 1993, Carcinogenesis.

[6]  G. Kelloff,et al.  Chemopreventive effect of oltipraz during different stages of experimental colon carcinogenesis induced by azoxymethane in male F344 rats. , 1993, Cancer research.

[7]  J. Yamashita,et al.  Increased expression of membrane‐associated phospholipase A2 shows malignant potential of human breast cancer cells , 1993, Cancer.

[8]  M. Stearns,et al.  Type IV collagenase (M(r) 72,000) expression in human prostate: benign and malignant tissue. , 1993, Cancer research.

[9]  T. Eling,et al.  Modulation of c-jun and jun-B messenger RNA and inhibition of DNA synthesis by prostaglandin E2 in Syrian hamster embryo cells. , 1992, Cancer research.

[10]  R. Schreiber,et al.  Cytokine modulation of immune activation associated suppression of macrophage cyclooxygenase activity in vivo. , 1992, Prostaglandins, leukotrienes, and essential fatty acids.

[11]  J. Tímár,et al.  The lipoxygenase metabolite 12(S)‐hete promotes αllbβ3integrin‐mediated tumor‐cell spreading on fibronectin , 1992 .

[12]  L. Marnett.  Aspirin and the potential role of prostaglandins in colon cancer. , 1992, Cancer research.

[13]  R. Goldman,et al.  Reactive oxygen species are involved in the activation of cellular phospholipase A2 , 1992, FEBS letters.

[14]  M. Fukushima.  Biological activities and mechanisms of action of PGJ2 and related compounds: an update. , 1992, Prostaglandins, leukotrienes, and essential fatty acids.

[15]  W. Smith.  Prostanoid biosynthesis and mechanisms of action. , 1992, The American journal of physiology.

[16]  E. Kohn,et al.  In vivo efficacy of a novel inhibitor of selected signal transduction pathways including calcium, arachidonate, and inositol phosphates. , 1992, Cancer research.

[17]  P. Young,et al.  The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor. , 1992, International journal of immunopharmacology.

[18]  A. Mukherjee,et al.  Regulation of extracellular phospholipase A2 activity: implications for inflammatory diseases. , 1992, DNA and cell biology.

[19]  R. Estabrook,et al.  Cytochrome P450 and the arachidonate cascade 1 , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  D. Rose,et al.  Effect of dietary fat on human breast cancer growth and lung metastasis in nude mice. , 1991, Journal of the National Cancer Institute.

[21]  E. Kohn,et al.  The antiproliferative and antimetastatic compound L651582 inhibits muscarinic acetylcholine receptor-stimulated calcium influx and arachidonic acid release. , 1991, The Journal of pharmacology and experimental therapeutics.

[22]  R. Tamargo,et al.  Angiogenesis inhibition by minocycline. , 1991, Cancer research.

[23]  D. Rose,et al.  Effects of fatty acids and inhibitors of eicosanoid synthesis on the growth of a human breast cancer cell line in culture. , 1990, Cancer research.

[24]  H. Kusaka,et al.  Relationship between blood plasma prostaglandin E2 and liver and lung metastases in colorectal cancer , 1990, Diseases of the colon and rectum.

[25]  L. Ellis,et al.  Inhibition of Tumor Growth and Metastasis by Chronic Intravenous Infusion of Prostaglandin E1 , 1990, Annals of surgery.

[26]  M. Young,et al.  Association of a functional prostaglandin E2-protein kinase A coupling with responsiveness of metastatic Lewis lung carcinoma variants to prostaglandin E2 and to prostaglandin E2-producing nonmetastatic Lewis lung carcinoma variants. , 1990, Cancer research.

[27]  L. Ellis,et al.  Differential role of prostaglandin E1 on tumor metastasis. , 1990, The Journal of surgical research.

[28]  Eveline,et al.  The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthases. , 1990, The Journal of biological chemistry.

[29]  D. Hwang.  Essential fatty acids and immune response , 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  K. Glaser,et al.  Inhibition studies on the membrane-associated phospholipase A2 in vitro and prostaglandin E2 production in vivo of the macrophage-like P388D1 cell. Effects of manoalide, 7,7-dimethyl-5,8-eicosadienoic acid, and p-bromophenacyl bromide. , 1989, The Journal of biological chemistry.

[31]  L. Kopeikina,et al.  PGE2 and PGA2 affect the allosteric properties and the activities of calmodulin-dependent guanylate cyclase and Ca2+-stimulated ATPase of Walker-256 tumour microsomal membranes. , 1989, Anticancer Research.

[32]  W. Smith,et al.  The eicosanoids and their biochemical mechanisms of action. , 1989, The Biochemical journal.

[33]  N. Fusenig,et al.  Tumor induction in initiated mouse skin by phorbol esters and methyl methanesulfonate: correlation between chromosomal damage and conversion ('stage I of tumor promotion') in vivo. , 1989, Carcinogenesis.

[34]  M. Boyd,et al.  Evidence for prostanoid biosynthesis as a biochemical feature of certain subclasses of non-small cell carcinomas of the lung as determined in established cell lines derived from human lung tumors. , 1989, Cancer research.

[35]  Maca Rd.  Inhibition of the growth of Lewis lung carcinoma by indomethacin in conventional, nude, and beige mice. , 1988 .

[36]  R. Chapkin,et al.  Inhibition of growth and linoleate-enhanced metastasis of a transplantable mouse mammary tumor by indomethacin. , 1988, Cancer letters.

[37]  M. Young,et al.  Regulation of tumor-induced myelopoiesis and the associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma by prostaglandin E2. , 1988, Cancer research.

[38]  A. Partin,et al.  Early cell motility changes associated with an increase in metastatic ability in rat prostatic cancer cells transfected with the v-Harvey-ras oncogene. , 1988, Cancer research.

[39]  R. Branch,et al.  Clinical implications of prostaglandin and thromboxane A2 formation (2). , 1988, The New England journal of medicine.

[40]  M. Boyd,et al.  Profiles of prostaglandin biosynthesis in sixteen established cell lines derived from human lung, colon, prostate, and ovarian tumors. , 1988, Cancer research.

[41]  A. Partin,et al.  Metastatic potential prediction by a visual grading system of cell motility: prospective validation in the Dunning R-3327 prostatic adenocarcinoma model. , 1988, Cancer research.

[42]  E. Dennis,et al.  Kinetic analysis of the Ca2+-dependent, membrane-bound, macrophage phospholipase A2 and the effects of arachidonic acid. , 1988, The Journal of biological chemistry.

[43]  S. Nandi,et al.  Proliferative effects of insulin and epidermal growth factor on mouse mammary epithelial cells in primary culture. Enhancement by hydroxyeicosatetraenoic acids and synergism with prostaglandin E2. , 1988, The Journal of biological chemistry.

[44]  A. Harris,et al.  Plasma prostaglandins in lung cancer. , 1988, European journal of cancer & clinical oncology.

[45]  M. Boyd,et al.  Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. , 1988, Cancer research.

[46]  M. Boyd,et al.  Evidence for thromboxane biosynthesis in established cell lines derived from human lung adenocarcinomas. , 1988, Cancer research.

[47]  E. Costa,et al.  Impairment of learning behavior in rats by nmda receptor antagonists radial maze and passive avoidance tests , 1988 .

[48]  P. Heinonen,et al.  Prostanoids and cyclic nucleotides in malignant and benign ovarian tumors , 1988, Medical oncology and tumor pharmacotherapy.

[49]  I. Nabi,et al.  Loss of metastatic responsiveness to cell shape modulation in a newly characterized B16 melanoma adhesive cell variant. , 1988, Cancer research.

[50]  S. Fischer,et al.  Phorbol ester induction of 8-lipoxygenase in inbred SENCAR (SSIN) but not C57BL/6J mice correlated with hyperplasia, edema, and oxidant generation but not ornithine decarboxylase induction. , 1988, Cancer research.

[51]  R. Chidambaram,et al.  Metal mediated routes to 5-membered rings , 1988 .

[52]  L. S. Liebeskind,et al.  A stereoselective, palladium-catalyzed route to 4-oxygenated 5-alkylidenecyclopentenones and 3-oxygenated 2-alkylideneindanones , 1987 .

[53]  D. Mccormick,et al.  Nordihydroguaiaretic acid suppression of rat mammary carcinogenesis induced by N-methyl-N-nitrosourea. , 1987, Cancer letters.

[54]  S. Dahlén,et al.  Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. , 1987, Science.

[55]  J. Vane,et al.  Inflammation and the mechanism of action of anti‐inflammatory drugs , 1987, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[56]  M. Boyd,et al.  Metabolism of arachidonic acid in human lung cancer cell lines. , 1987, Cancer research.

[57]  M. Young,et al.  Effect of prostaglandin E2-producing nonmetastatic Lewis lung carcinoma cells on the migration of prostaglandin E2-responsive metastatic Lewis lung carcinoma cells. , 1987, Cancer research.

[58]  S. Narumiya,et al.  Site and mechanism of growth inhibition by prostaglandins. III. Distribution and binding of prostaglandin A2 and delta 12-prostaglandin J2 in nuclei. , 1987, The Journal of pharmacology and experimental therapeutics.

[59]  L. Daniel,et al.  Evidence of protein kinase C involvement in phorbol diester-stimulated arachidonic acid release and prostaglandin synthesis. , 1987, The Journal of biological chemistry.

[60]  A. Fulton.  Interactions of natural effector cells and prostaglandins in the control of metastasis. , 1987, Journal of the National Cancer Institute.

[61]  B. Rabin,et al.  Prostaglandin E2 of the Upper Aerodigestive Tract , 1987, The Annals of otology, rhinology, and laryngology.

[62]  S. Nandi,et al.  Linoleate metabolites enhance the in vitro proliferative response of mouse mammary epithelial cells to epidermal growth factor. , 1987, The Journal of biological chemistry.

[63]  M. Rustin,et al.  Arachidonic acid metabolites in cutaneous carcinomas. , 1987, Archives of dermatology.

[64]  S. Narumiya,et al.  Site and mechanism of growth inhibition by prostaglandins. II. Temperature-dependent transfer of a cyclopentenone prostaglandin to nuclei. , 1986, The Journal of pharmacology and experimental therapeutics.

[65]  S. Narumiya,et al.  Site and mechanism of growth inhibition by prostaglandins. I. Active transport and intracellular accumulation of cyclopentenone prostaglandins, a reaction leading to growth inhibition. , 1986, The Journal of pharmacology and experimental therapeutics.

[66]  G. Martin,et al.  Basement membrane and the invasive activity of metastatic tumor cells. , 1986, Journal of the National Cancer Institute.

[67]  K. Kato,et al.  Inhibition of human ovarian cancer cell growth in vitro and in nude mice by prostaglandin D2. , 1986, Cancer research.

[68]  J. Larrick,et al.  Regulation of macrophage tumor necrosis factor production by prostaglandin E2. , 1986, Biochemical and biophysical research communications.

[69]  N. Swanson,et al.  Arachidonic acid metabolites in cutaneous carcinomas. Evidence suggesting that elevated levels of prostaglandins in basal cell carcinomas are associated with an aggressive growth pattern. , 1986, Archives of dermatology.

[70]  R. Schreiber,et al.  Requirement of endogenous interferon-gamma production for resolution of Listeria monocytogenes infection. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[71]  G. Heppner,et al.  Relationships of prostaglandin E and natural killer sensitivity to metastatic potential in murine mammary adenocarcinomas. , 1985, Cancer research.

[72]  R. Hilf,et al.  Failure of indomethacin to inhibit growth of the R3230AC mammary tumor in rats. , 1985, Journal of the National Cancer Institute.

[73]  J. Watson,et al.  Prostaglandins, steroids and human mammary cancer. , 1985, European journal of cancer & clinical oncology.

[74]  J. Goldenring,et al.  Phosphorylation of Microtubule‐Associated Protein 2 at Distinct Sites by Calmodulin‐Dependent and Cyclic‐AMP‐Dependent Kinases , 1985, Journal of neurochemistry.

[75]  R. Fanelli,et al.  Prostaglandin and thromboxane synthesis by Lewis lung carcinoma during growth. , 1985, Cancer research.

[76]  M. Young,et al.  Relationships between morphology, dissemination, migration, and prostaglandin E2 secretion by cloned variants of Lewis lung carcinoma. , 1985, Cancer research.

[77]  I. Vergote,et al.  Prostaglandin F2 alpha in benign and malignant breast tumours. , 1985, British Journal of Cancer.

[78]  J. Varani,et al.  Directional motility in strongly malignant murine tumor cells , 1985, International journal of cancer.

[79]  D. Mccormick,et al.  Modulation of rat mammary carcinogenesis by indomethacin. , 1985, Cancer research.

[80]  S. Nigam,et al.  The concentrations of 6-keto-PGF1 alpha and TXB2 in plasma samples from patients with benign and malignant tumours of the breast. , 1985, Prostaglandins.

[81]  R. Schreiber,et al.  Monoclonal antibodies to murine gamma-interferon which differentially modulate macrophage activation and antiviral activity. , 1985, Journal of immunology.

[82]  T. Martin,et al.  Characteristics of selective activation of cyclic AMP-dependent protein kinase isoenzymes by calcitonin and prostaglandin E2 in human breast cancer cells. , 1984, The Biochemical journal.

[83]  N. Berlinger.  Deficient immunity in head and neck cancer due to excessive monocyte production of prostaglandins , 1984, The Laryngoscope.

[84]  J. Sheller,et al.  Arachidonic acid metabolites in the healthy and diseased lung. , 1984, The American journal of the medical sciences.

[85]  A. Fulton.  In vivo effects of indomethacin on the growth of murine mammary tumors. , 1984, Cancer research.

[86]  R. Paoletti,et al.  Icosanoids and Cancer , 1984 .

[87]  A. Fulton.  Effects of indomethacin on the growth of cultured mammary tumors , 1984, International journal of cancer.

[88]  S. Russell,et al.  Both the Kind and Magnitude of Stimulus Are Important in Overcoming the Negative Regulation of Macrophage Activation by PGE2 , 1984, Journal of leukocyte biology.

[89]  R. Ardaillou,et al.  Reactive oxygen production by cultured rat glomerular mesangial cells during phagocytosis is associated with stimulation of lipoxygenase activity , 1983, The Journal of experimental medicine.

[90]  D. Mccormick,et al.  Inhibition of mammary carcinogenesis by flurbiprofen, a non-steroidal antiinflammatory agent. , 1983, British Journal of Cancer.

[91]  H. Thaler,et al.  Prostaglandins in breast cancer: relationship to disease stage and hormone status. , 1983, British Journal of Cancer.

[92]  S. Kosanke,et al.  Influence of dietary fat and indomethacin on the growth of transplantable mammary tumors in rats. , 1983, Cancer research.

[93]  F. Meyskens,et al.  In vitro modulation of human and murine melanoma growth by prostanoid analogues. , 1983, Prostaglandins.

[94]  C. Nathan,et al.  Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity , 1983, The Journal of experimental medicine.

[95]  T. Littler.  Anti-rheumatic drugs. , 1983, Pharmacology & therapeutics.

[96]  M. Ip,et al.  Effect of the prostaglandin synthetase inhibitor indomethacin on 7,12-dimethylbenz(a)anthracene-induced mammary tumorigenesis in rats fed different levels of fat. , 1983, Cancer research.

[97]  R. Miller,et al.  Recombinant immune interferon increases immunoglobulin G Fc receptors on cultured human mononuclear phagocytes. , 1983, The Journal of clinical investigation.

[98]  P. P. Jones,et al.  Induction of Ia and H-2 antigens on a macrophage cell line by immune interferon. , 1983, Journal of immunology.

[99]  F. Bettens,et al.  Lymphokine regulation of activated (G1) lymphocytes. I. Prostaglandin E2-induced inhibition of interleukin 2 production. , 1983, Journal of immunology.

[100]  W. Whimster,et al.  Prostaglandins and human lung carcinomas. , 1982, British Journal of Cancer.

[101]  I. Ahnfelt-Rønne,et al.  Multiple effects of a new anti-inflammatory agent, timegadine, on arachidonic acid release and metabolism in neutrophils and platelets. , 1982, Biochemical pharmacology.

[102]  S. Narumiya,et al.  Prostaglandin D2, a potential antineoplastic agent. , 1982, Biochemical and biophysical research communications.

[103]  K. Honn,et al.  Thromboxanes and prostacyclin: positive and negative modulators of tumor growth. , 1981, Biochemical and biophysical research communications.

[104]  E. Corey,et al.  Functional characterization of synthetic leukotriene B and its stereochemical isomers , 1981, The Journal of experimental medicine.

[105]  A. Rober.  Prostaglandins and related lipids , 1981 .

[106]  J. Goodwin.  PROSTAGLANDINS AND IMMUNITY , 1981, The Lancet.

[107]  S. Russell,et al.  Lymphokine maintains macrophage activation for tumor cell killing by interfering with the negative regulatory effect of prostaglandin E2. , 1981, Journal of immunology.

[108]  L. Marnett,et al.  Prostaglandins and cancer: a review of tumor initiation through tumor metastasis. , 1981, Prostaglandins.

[109]  S. Russell,et al.  Macrophage-mediated tumor cell killing: regulation of expression of cytolytic activity by prostaglandin E. , 1981, Journal of immunology.

[110]  E. Unanue,et al.  Demonstration of a soluble mediator that induces exudates rich in Ia- positive macrophages , 1980, The Journal of experimental medicine.

[111]  E. Corey,et al.  Leukotriene B. Total synthesis and assignment of stereochemistry , 1980 .

[112]  J. Jacquemier,et al.  Prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. , 1980, Journal of the National Cancer Institute.

[113]  B. Samuelsson,et al.  The inhibitory effects of BW 755C on arachidonic acid metabolism in human polymorphonuclear leukocytes , 1980, FEBS letters.

[114]  A. Verma,et al.  Inhibition by prostaglandin synthesis inhibitors of the induction of epidermal ornithine decarboxylase activity, the accumulation of prostaglandins, and tumor promotion caused by 12-O-tetradecanoylphorbol-13-acetate. , 1980, Cancer research.

[115]  R. Carter,et al.  Prostaglandin-like material extracted from squamous carcinomas of the head and neck. , 1980, British Journal of Cancer.

[116]  F. Fitzpatrick,et al.  Prostaglandin D2 controls pulmonary metastasis of malignant melanoma cells , 1979, Nature.

[117]  S. Abraham,et al.  Effect of dietary polyunsaturated fatty acids on growth of mammary adenocarcinomas in mice and rats. , 1979, Cancer research.

[118]  D. Leaper,et al.  Cancer growth, response to treatment and survival time in mice: beneficial effect of the prostaglandin synthesis inhibitor flurbiprofen. , 1979, Prostaglandins.

[119]  K. Gréen,et al.  DETERMINATION OF PROSTAGLANDINS IN BODY FLUIDS AND TISSUES , 1979, Acta obstetricia et gynecologica Scandinavica. Supplement.

[120]  M. Meltzer,et al.  Macrophage activation for tumor cytotoxicity: development of macrophage cytotoxic activity requires completion of a sequence of short-lived intermediary reactions. , 1978, Journal of immunology.

[121]  F. Marks,et al.  Indomethacin inhibition of cell proliferation induced by the phorbolester TPA is reversed by prostaglandin E2 in mouse epidermis in vivo. , 1978, Biochemical and biophysical research communications.

[122]  J. Salomon,et al.  Mechanism of inhibition of tumour growth by aspirin and indomethacin. , 1978, British Journal of Cancer.

[123]  A. Verma,et al.  Prostaglandins and skin tumor promotion: inhibition of tumor promoter-induced ornithine decarboxylase activity in epidermis by inhibitors of prostaglandin synthesis. , 1977, Biochemical and biophysical research communications.

[124]  O. Plescia,et al.  Tumor-mediated immunosuppression: prevention by inhibitors of prostaglandin synthesis. , 1977, Prostaglandins.

[125]  T. Żebro,et al.  PROSTAGLANDINS AND BREAST CANCER , 1977, The Lancet.

[126]  P. Hedqvist,et al.  Aspects of Prostaglandin Function in the Lung , 1977 .

[127]  J. Oates,et al.  Prostaglandins as mediators of hypercalcemia associated with certain types of cancer. , 1975, The New England journal of medicine.

[128]  L. Rome,et al.  Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[129]  P. Majerus,et al.  The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. , 1975, The Journal of clinical investigation.

[130]  P. Rudland,et al.  Initiation of cell proliferation in cultured mouse fibroblasts by prostaglandin F2alpha. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[131]  Allan H. Smith,et al.  Subversion of immune system by tumor cells and role of prostaglandins. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[132]  D. Nugteren.  Arachidonate lipoxygenase in blood platelets. , 1975, Biochimica et biophysica acta.

[133]  M. Hamberg,et al.  Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets. , 1974, Proceedings of the National Academy of Sciences of the United States of America.

[134]  R. Flower.  Drugs which inhibit prostaglandin biosynthesis. , 1974, Pharmacological reviews.

[135]  M. Hamberg,et al.  Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. , 1974, Proceedings of the National Academy of Sciences of the United States of America.

[136]  D. Nugteren,et al.  Isolation and properties of intermediates in prostaglandin biosynthesis. , 1973, Biochimica et biophysica acta.

[137]  J. Vane,et al.  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.

[138]  D. V. van Dorp,et al.  The action of prostaglandin synthetase on 2-arachidonyl-lecithin. , 1968, Biochimica et biophysica acta.

[139]  B. Samuelsson,et al.  Phospholipid precursors of prostaglandins. , 1968, Biochimica et biophysica acta.

[140]  T. Tong,et al.  Cancer statistics, 1994 , 1994, CA: a cancer journal for clinicians.

[141]  M. Ip,et al.  Regulation of proliferation of rat mammary tumor cells by inhibitors of cyclooxygenase and lipoxygenase. , 1992, Prostaglandins, leukotrienes, and essential fatty acids.

[142]  M. Boyd,et al.  Fatty Acid Cyclooxygenase Metabolism of Arachidonic Acid in Human Tumor Cells , 1991 .

[143]  B. Conde,et al.  Modulation of cell growth and differentiation induced by prostaglandin D2 in the glioma cell line C6. , 1991, Anticancer Research.

[144]  K. Honn,et al.  Eicosanoids and Other Bioactive Lipids in Cancer and Radiation Injury , 1991, Developments in Oncology.

[145]  R. Abbate,et al.  Prostaglandins in squamous cell carcinoma of the larynx: tumor and peritumor synthesis. , 1990, Prostaglandins, leukotrienes, and essential fatty acids.

[146]  E. Dennis.  Modification of the arachidonic acid cascade through phospholipase A2 dependent mechanisms. , 1990, Advances in prostaglandin, thromboxane, and leukotriene research.

[147]  E. Okuda‐Ashitaka,et al.  Cyclic AMP-mediated inhibition of cell growth by prostaglandin D2 in a fibroblastic cell line (EBTr). , 1990, Eicosanoids.

[148]  M. Fukushima.  Prostaglandin J2--anti-tumour and anti-viral activities and the mechanisms involved. , 1990, Eicosanoids.

[149]  A. Mukherjee.  Biochemistry, Molecular Biology, and Physiology of Phospholipase A2 and Its Regulatory Factors , 1990, Advances in Experimental Medicine and Biology.

[150]  K. Honn,et al.  Lipoxygenase regulation of membrane expression of tumor cell glycoproteins and subsequent metastasis. , 1989, Advances in prostaglandin, thromboxane, and leukotriene research.

[151]  E. Cerise,et al.  Sulindac for polyposis of the colon. , 1989, American journal of surgery.

[152]  C. Sorg.  Macrophage-derived cell regulatory factors , 1989 .

[153]  M. De,et al.  Relationship of in vitro cell motility and colonization potential in a mouse colon adenocarcinoma (MCA-38) cell line. , 1988 .

[154]  Fulton Am.  The role of eicosanoids in tumor metastasis. , 1988 .

[155]  P. Needleman,et al.  Arachidonic acid metabolism. , 1986, Annual review of biochemistry.

[156]  J. Ceuppens,et al.  Prostaglandins, Cellular Immunity and Cancer , 1985 .

[157]  L. Hokin.  Receptors and phosphoinositide-generated second messengers. , 1985, Annual review of biochemistry.

[158]  C. Balch,et al.  Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patients. , 1984, Surgery.

[159]  W. Lands,et al.  Chapter 6 Inhibitors and activators of prostaglandin biosynthesis , 1983 .

[160]  Bonnie F. Sloane,et al.  Prostacyclin and thromboxanes. Implications for their role in tumor cell metastasis. , 1983, Biochemical pharmacology.

[161]  Robert A. Lewis.  PHYSIOLOGIC AND PATHOBIOLOGIC EFFECTS OF LEUKOTRIENES C4, D4, AND E4 , 1983 .

[162]  E. Granström,et al.  Prostaglandins and related substances , 1983 .

[163]  K. Honn,et al.  Control of tumor growth and metastasis with prostacyclin and thromboxane synthetase inhibitors: evidence for a new antitumor and antimetastatic agent (BAY g 6575). , 1982, Progress in clinical and biological research.

[164]  A. Ordinas,et al.  Interaction of platelets and tumour cells , 1982 .

[165]  M. Young,et al.  Enhancement in immunity of tumor bearing mice by immunization against prostaglandin E2. , 1982, Immunological communications.

[166]  C. Balch,et al.  Indomethacin enhancement of immunocompetence in melanoma patients. , 1981, Surgery.

[167]  L. Levine.  Arachidonic acid transformation and tumor production. , 1981, Advances in cancer research.

[168]  T. Slaga,et al.  Modulation of prostaglandin synthesis and tumor promotion , 1981 .

[169]  P. Majerus,et al.  Aspirin as a quantitative acetylating reagent for the fatty acid oxygenase that forms prostaglandins. , 1976, Prostaglandins.

[170]  R. Stein-Werblowsky.  Prostaglandin and cancer. , 1974, Oncology.